Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 301

1.

Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies.

Riddle MC, Vlajnic A, Zhou R, Rosenstock J.

Diabetes Obes Metab. 2013 Sep;15(9):819-25. doi: 10.1111/dom.12096. Epub 2013 Apr 5.

PMID:
23489438
2.

Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus.

Karl DM, Gill J, Zhou R, Riddle MC.

Diabetes Obes Metab. 2013 Jul;15(7):622-8. doi: 10.1111/dom.12072. Epub 2013 Feb 24.

PMID:
23350795
3.
4.

Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.

Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P.

Diabetes Obes Metab. 2013 Aug;15(8):729-36. doi: 10.1111/dom.12083. Epub 2013 Mar 13.

PMID:
23421331
5.

Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin.

Dailey GE, Gao L, Aurand L, Garg SK.

Diabetes Obes Metab. 2013 Dec;15(12):1085-92. doi: 10.1111/dom.12131. Epub 2013 Jun 12.

PMID:
23683002
6.

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.

Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC.

Diabetes Obes Metab. 2015 Jan;17(1):15-22. doi: 10.1111/dom.12329. Epub 2014 Jul 12.

7.
8.

Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.

Arakaki RF, Blevins TC, Wise JK, Liljenquist DR, Jiang HH, Jacobson JG, Martin SA, Jackson JA.

Diabetes Obes Metab. 2014 Jun;16(6):510-8. doi: 10.1111/dom.12242. Epub 2013 Dec 29.

9.
10.
11.

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, Ping L, Rosenstock J.

Diabetes Care. 2013 Sep;36(9):2497-503. doi: 10.2337/dc12-2462. Epub 2013 Apr 5.

12.

Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes.

Shaefer CF, Reid TS, Dailey G, Mabrey ME, Vlajnic A, Stuhr A, Stewart J, Zhou R.

Postgrad Med. 2014 Oct;126(6):93-105. doi: 10.3810/pgm.2014.10.2824.

PMID:
25414938
13.

Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.

Banerji MA, Baron MA, Gao L, Blonde L.

Postgrad Med. 2014 May;126(3):111-25. doi: 10.3810/pgm.2014.05.2761.

PMID:
24918797
14.

Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.

Koivisto V, Cleall S, Pontiroli AE, Giugliano D.

Diabetes Obes Metab. 2011 Dec;13(12):1149-57. doi: 10.1111/j.1463-1326.2011.01484.x.

PMID:
21819517
15.

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.

Owens DR, Traylor L, Dain MP, Landgraf W.

Diabetes Res Clin Pract. 2014 Nov;106(2):264-74. doi: 10.1016/j.diabres.2014.08.003. Epub 2014 Aug 12.

16.

Gender-based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes: results from patient-level pooled data of six randomized controlled trials.

Kautzky-Willer A, Kosi L, Lin J, Mihaljevic R.

Diabetes Obes Metab. 2015 Jun;17(6):533-40. doi: 10.1111/dom.12449. Epub 2015 Mar 20.

PMID:
25678212
18.

Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.

Davies M, Lavalle-González F, Storms F, Gomis R; AT.LANTUS Study Group.

Diabetes Obes Metab. 2008 May;10(5):387-99. doi: 10.1111/j.1463-1326.2008.00873.x. Epub 2008 Mar 18.

PMID:
18355327
20.

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.

Fonseca V, Gill J, Zhou R, Leahy J.

Diabetes Obes Metab. 2011 Sep;13(9):814-22. doi: 10.1111/j.1463-1326.2011.01412.x.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk